These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 23538180

  • 1. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
    Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C.
    Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
    [Abstract] [Full Text] [Related]

  • 2. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P, Hyde C.
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [Abstract] [Full Text] [Related]

  • 3. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
    Lawrence D, Maschio M, Leahy KJ, Yunger S, Easaw JC, Weinstein MC.
    J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
    [Abstract] [Full Text] [Related]

  • 4. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ, Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group, Australasian Gastrointestinal Interest Group.
    J Natl Cancer Inst; 2009 Sep 02; 101(17):1182-92. PubMed ID: 19666851
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
    Vijayaraghavan A, Efrusy MB, Göke B, Kirchner T, Santas CC, Goldberg RM.
    Int J Cancer; 2012 Jul 15; 131(2):438-45. PubMed ID: 21898389
    [Abstract] [Full Text] [Related]

  • 6. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P, Jones R, Paisley S, Carroll C.
    Health Technol Assess; 2007 Mar 15; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
    Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle M.
    Health Technol Assess; 2017 Jun 15; 21(38):1-294. PubMed ID: 28682222
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.
    Shiroiwa T, Motoo Y, Tsutani K.
    Mol Diagn Ther; 2010 Dec 01; 14(6):375-84. PubMed ID: 21275455
    [Abstract] [Full Text] [Related]

  • 12. Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece.
    Fragoulakis V, Papagiannopoulou V, Kourlaba G, Maniadakis N, Fountzilas G.
    Clin Ther; 2012 Oct 01; 34(10):2132-42. PubMed ID: 23063374
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
    Sohn BS, Kim TW, Lee JL, Ryu MH, Chang HM, Kang YK, Park HS, Na YS, Jang SJ, Kim JC, Lee JS.
    Oncology; 2009 Oct 01; 77(3-4):224-30. PubMed ID: 19738388
    [Abstract] [Full Text] [Related]

  • 18. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
    Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F.
    J Clin Oncol; 2009 Mar 01; 27(7):1122-9. PubMed ID: 19164213
    [Abstract] [Full Text] [Related]

  • 19. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
    Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW.
    Oncologist; 2012 Mar 01; 17(1):14. PubMed ID: 22210091
    [Abstract] [Full Text] [Related]

  • 20. [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].
    Asai H, Shinozaki E, Nozaki A, Watanabe T, Suenaga M, Matuzaka S, Chin K, Mizunuma N, Yasukawa M, Hatake K.
    Gan To Kagaku Ryoho; 2011 Aug 01; 38(8):1285-91. PubMed ID: 21829065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.